$150K to Myron Evans at Seattle Children's for Medulloblastoma research

Overcoming Radioresistance in Relapsed High-Risk Medulloblastoma via YBX1 Inhibition

Myron Evans, Ph.D.

Seattle Children’s Hospital

$150,000

This innovative medulloblastoma research project is aimed at overcoming treatment resistance in children with the highest-risk forms of this aggressive brain tumor. Dr. Evans is evaluating a novel drug that targets YBX1, a protein that helps tumor cells survive radiation therapy and contributes to disease recurrence. By combining YBX1 inhibition with radiation, the team hopes to improve tumor control while creating opportunities to reduce radiation exposure and its long-term side effects. This work could lead to more effective and less toxic treatment options for kids with high-risk medulloblastoma. We’re looking for a future where all forms of medulloblastoma are highly responsive to therapy, and less damaging to kids’ bodies.

‍